Single institutional retrospective analysis: treatment of choroidal melanomas with cobalt-60 brachytherapy

Arquivos Brasileiros de Oftalmologia

Antônio Cássio Assis Pellizzon²  João Victor Salvajoli²  Paulo Eduardo Novaes²  Ricardo Fogaroli²  Robson Ferrigno²  Maria Aparecida Conte Maia²  Marta Motono Chojniak¹  Clélia Maria Erwene¹ 

[1] ,Hospital do Câncer - AC Camargo Centro de Tratamento Pesquisa Department of Radiation Oncology

关键词: Choroid neoplasms;    Melanoma;    Cobalt radioisotopes;    Eye enucleation;    Brachytherapy;    Radiotherapy dosage;    Neoplasias da coróide;    Melanoma;    Radioisótopos de cobalto;    Enucleação ocular;    Braquiteraia;    Dosagem radioterapêutica;   

DOI  :  10.1590/S0004-27492004000300015

来源: SciELO

【 摘 要 】

PURPOSE: To evaluate the outcome of patients with choroidal melanoma treated with conservative therapy with brachytherapy (episcleral Co-60 plaque therapy) at the "Hospital do Cancer" São Paulo, Brazil. METHODS: We evaluated 102 patients consecutively treated from January, 1999 to June, 1999. Median age, maximum tumor base diameter and apex size were 55.5 years, 9.75 mm and 5 mm, respectively. Doses at the base of the tumor, including 1 mm of sclera, ranged from 157 to 487 Gy (median 284.5 Gy) and to the apex from 37 to 220 Gy (median 106 Gy). RESULTS: The crude eye preservation rate with conservative therapy alone was 78.5%. Five-year overall actuarial survival rate was 92.2% and eye conservation rate was 78%. Side effects were mostly an uncomplicated retinopathy in 39/102 patients (38.2%); macular degeneration or scarring led to poor central vision in 31/102 patients (30.3%) of cases. CONCLUSION: Our experience with cobalt-60 plaque brachytherapy achieved a satisfactory rate of local tumor control, despite the oversized base diameters of treated tumors.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License